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Summary The serum values of the tumour markers carcinoembryonic antigen (CEA), cancer-associated
carboanhydrate antigens CA 50 and CA 242 were evaluated in 193 patients with hepatopancreato-biliary
diseases by receiver operating characteristic (ROC) curve analysis in order to compare their diagnostic
accuracy in pancreatic cancer (n = 26), and to define optimal cut-off levels for the serum values of these
tumour markers in the diagnosis of pancreatic cancer. The ROC analysis showed that all marker tests are
considerably sensitive (77-81%) at the specificity level of 80%. The CA 242 test was more sensitive than CEA
and CA 50 at high specificity levels (>0.90) but slightly less sensitive at low specificity levels (<0.60). The
CEA test and CA 50 test performed equally well at high and low specificity levels. According to this study, it
would seem optimal to use the cut-off level of 4.1 ng ml1' for CEA, and the level of 137 U ml-I for CA 50,
since they gave a sensitivity of 77% at the specificity levels of 83% and 84%, respectively. For CA 242 the
optimal cut-off level was 21 U ml- ', which gave a sensitivity and specificity of 81%. In conclusion, the results
of ROC curve analysis suggest that the CA 242 test has an advantage over CEA and CA 50 because of its
higher specificity in pancreatic cancer. In addition, it would seem reasonable to use higher cut-off values than
what has been recommended for CEA and CA 50 in the diagnosis of pancreatic cancer, but for CA 242 the
recommended cut-off level of 20 U ml1' seems appropriate.
Evaluation of the results of various tumour marker studies is
often problematic because of variance in the patient popula-
tions and in the cut-off values used in these studies. In many
studies the sera of heterogenous populations (healthy blood
donors, laboratory staff, patients with various types of
cancer) have been used as reference patient material. This
seems, however, unsatisfactory unless blind screening
methods for the whole population are being sought. The
diagnostic accuracy and cut-off values of the tumour marker
tests should be tested in a relevant patient population
(Roberts, 1986). In practice - and not least for reasons of
economy - we should be able to focus these tests on patient
groups with a high risk ofcertain types of cancer. The use of
receiver operating characteristic (ROC) curve analysis has
gained increasing popularity among clinical investigators
(Feinstein, 1985). It makes possible comparisons of the sen-
sitivity and specificity of different tests independently of the
relative incidences of the diseases and of the cut-off level.
This prospective series of 193 consecutive patients with jaun-
dice and/or cholestasis (n = 133), and with a suspicion of
chronic pancreatitis or pancreatic tumour (n = 60) offers a
good opportunity for such an analysis with regard to the
diagnosis of pancreatic cancer. We measured the serum
values of carcinoembryonic antigen (CEA), cancer associated
carboanhydrate antigens CA 50 and CA 242 in these
patients, and compared them with the help of ROC curves.
Patients
The patient population of this prospective study consisted of
a consecutive series of patients admitted to or attending
Kuopio University Hospital during the two-and-a-half year
period from the beginning of December 1985 to the end of
May 1988. The limits for inclusion to the study were defined
as follows: a serum bilirubin level exceeding 40 micromoles
per litre (normal value in our laboratory < 17 jimol 1-'),
and/or serum alkaline phosphatase level above 350 IU -
(normal value in our laboratory <210 UI-) in relation to
serum gamma glutamyltranspeptidase level above 100 IU I-
(normal value in our laboratory <32 U 1'), or liver-specific
alkaline phosphatase elevated. In addition to these jaundiced
or cholestatic patients the following patients were included:
patients with a history of two or more episodes of acute
pancreatitis, patients who had continuous or recurring
abdominal pain with raised serum or urine amylase levels
measured at least three times, patients who had been
suspected to have a pancreatic tumour or chronic pancreatitis
in ultrasound or computed, tomography examination. Ex-
clusion criteria were: age less than 15 years, pregnancy, jaun-
dice developing in the intensive care unit, a history of recent
heart surgery, insufficient cooperation, acute alcoholic pan-
creatitis, disseminated malignancy, parenchymal liver disease
diagnosed within 2 days of admission, need for emergency
surgery. One hundred and ninety-three patients were included
altogether. The patients have been previously described in
detail (Pasanen et al., 1992). There were altogether 24
patients with the final diagnosis of carcinoma of the head of
the pancreas and two patients with the diagnosis of car-
cinoma of the ampulla of Vater.
Methods
Clinical assessment, laboratory tests, and imaging methods
(ultrasound, computed tomography and endoscopic retro-
grade cholangio-pancreatography) were performed as pre-
viously decribed (Pasanen et al., 1992). In addition, liver
biopsy was obtained or secretin-cerulein test was performed
if hepatocellular disease or chronic pancreatitis was sus-
pected. All the patients involved in the study were scheduled
for re-examination 6 months after entering the study, and the
clinical data of the hospital records were reviewed retrospec-
tively after a follow-up period of 2 years. The final diagnosis
of a pancreatic cancer or cancer of the ampulla of Vater was
based on histology in 16 cases, on cytology in three, on
operative or endoscopic macroscopic morphologic findings in
three, and on the imaging methods in four. The diagnosis of
chronic pancreatitis was based on histology in seven cases, on
cytology in one, on secretin-cerulein test in six, on the imag-
ing methods in 14 and on clinical course of the disease in six.
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Assays
Serum samples were obtained by venipuncture on the pat-
ient's admission to hospital before surgery or biopsy and all
serum samples were stored frozen (- 20°C) until analysed.
Serum CEA concentrations were determined by using
monoclonal antibody delayed immunofluorescence (TR-FIA,
Wallac, Turku, Finland). Serum CA 50 concentrations were
determined by using monoclonal antibody (C-50) delayed
immunofluorescence (TR-FIA, Wallac, Turku, Finland).
Serum CA 242 concentrations were determined by using a
dissociation-enhanced lanthidine fluoroimmunoassay pro-
totype kit (DELFIA; Pharmacia Diagnostics, Uppsala,
Sweden) (Nilsson et al., 1988). The assay was done according
to the protocol recommended by the manufacturer.
The diagnostic sensitivity, specificity, positive predictive
value (= PV+ ) and negative predictive value (=PV -)
were calculated according to the following formulas:
Sensitivity = TP/(TP + FN), Specificity = TN/(TN + FP),
Positive predictive value = TP/(TP + FP),
Negative predictive value = TN/(TN + FN).
(TP = true positive, TN = true negative, FP = false posi-
tive, FN = false negative).
Receiver operating characterstic (ROC) curves were construc-
ted by calculating the sensitivities (true positive rate) and
specificities (false positive rate) of the CEA, CA 50 and CA
242 assays at several cut-off points (Feinstein, 1985). The
differences in diagnostic accuracy between the marker tests
were measured by McNemar's test (Armitage & Berry, 1987).
Results
We have previously reported the results of the CEA, CA 50
and CA 242 assays in detail (Pasanen et al., 1992). High
serum marker levels were found in patients with pancreatic
cancer and in patients with cancer of the bile ducts, but
elevated values were also detected in patients with benign
extrahepatic jaundice or cholestasis, and in patients with
benign hepatocellular disease.
Comparison ofthe tests by ROC curves
ROC curves for CEA, CA 50 and CA 242 are presented in
Figure 1. The sensitivity of each marker was determined at
several specificity levels. The corresponding sensitivities and
actual cut-off points producing Figure 1 are given in Table I.
The results showed that CA 242 was significantly more sen-
sitive than CEA and CA 50 at high (>0.90) specificity levels
(at 95% specificity CA 242 vs CEA, P = 0.035, 95%
confidence limits - 0.52 and - 0.02; CA 242 vs CA 50,
P = 0.013, 95% confidence limits - 0.54 and - 0.07,
McNemar's test), but slightly less sensitive at low (<0.60)
specificity levels. At the specificity level of 80% the CA 242
test was still slightly more sensitive (81%) than CEA and CA
50 (both 77%).
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Figure 1 The value of serum CEA, CA 50 and CA 242
measurements in the diagnosis of pancreatic cancer (n =26)
among patients with benign (n = 151) and malignant (n = 42)
hepatopancreato-biliary diseases as analysed with the help of
ROC curves.
Determining the cut-offlevels
When we used the recommended cut-off value of 2.5 ng ml'
for CEA, two pancreatic cancers remained under this level
(sensitivity 92.3%), but 73 false positive diagnoses resulted
(the specificity 59.2%). According to the ROC analysis the
optimal cut-off level for CEA was 4.1 ng ml-', since up to
this level the specificity improved without essentially decreas-
ing the sensitivity, the resulting specificity being 83.2% and
sensitivity 77%. Between the limits of 2.5 ng ml-' and
4.1 ng ml-' there were 45 false positive diagnoses including
16 cases of choledochal stones, 11 of acute or chronic pan-
creatitis, and six of benign liver disease.
When the recommended cut-off level of 17 U ml-' was
used for CA 50, one pancreatic cancer remained undiag-
nosed, but 100 false positive diagnoses were made (sensitivity
96.1%, specificity 58.0%). In the ROC analysis the optimal
cut-off level was 137 U ml', which gave a specificity of
83.8% at the sensitivity level of 77%. Between the limits of
17 U ml' and 137 U ml' there were 40 false positive diag-
noses which comprised 22 cases of choledochal stones, 15 of
acute or chronic pancreatitis, and 11 of benign liver disease.
When we applied the recommended cut-off level of
20 U ml1' for CA 242, its sensitivity was 81% and specificity
79%. The sensitivity did not essentially improve even at the
specificity level of 60% (Figure 1). In the ROC analysis,
therefore, the optimal cut-off level for CA 242 was set to
21 U ml1', which gave a sensitivity of 81% at the same level
of specificity. There were three false positive diagnoses
between the levels of 20 U ml' and 21 U ml' in this series
Table I The sensitivities andcorresponding cut-offlevels for CEA, CA 50 and CA
242 tests in the detection of pancreatic cancer at specificity levels between
60-95%
Specificity (%)
95% 90% 85% 80% 70% 60%
Sensitivity(%) CEA 34.6 57.6 65.3 76.9 80.7 92.3
Cut-off 7.2 5.2 4.5 3.6 3.0 2.6
(ngml-')
CA 50 30.7 50.0 73.0 76.9 88.4 88.4
Cut-off 716.2 271.7 154.1 120.2 67.9 41.6
(Uml,')
CA 242 61.5 61.5 73.0 80.7 80.7 84.6
Cut-off 62.8 30.5 23.0 20.5 13.8 11.1
(Uml-')854 P.A. PASANEN et al.
(two cases of choledochal stones and one of benign liver
disease).
Discussion
The reference and the cut-off values are produced for
clinicians to support clinical decision making. The selected
cut-off value of a laboratory test should provide the best
diagnostic performance for either ruling out or ruling in the
particular disease. The ROC curve analysis is a graphic
method which can be used to determine this optimal cut-off
level (Feinstein, 1985). In addition, it can be used in graphic
comparison of the sensitivity and specificity of different diag-
nostic tests. This method has been successfully applied for
comparing tumour marker tests (Eskelinen et al., 1989; Nils-
son et al., 1992; Haglund et al., 1992).
During recent years various serological markers have been
developed in the diagnosis of pancreatic cancer and in many
studies considerably high sensitivities and specificities have
been reported. Serum CEA and CA 50 are among the most
intensively studied tumour markers and their role as
reference markers is established (Kalser et al., 1978; Hansen
et al., 1974; Lindholm et al., 1983; Jalanko et al., 1985;
Masson et al., 1990; Haglund et al., 1992). CA 242 is a novel
tumour marker which has proved promising because of its
high specificity (Haglund et al., 1989; Kuusela et al., 1991;
Nilsson et al., 1992; Pasanen et al., 1992). Evaluation ofthese
marker studies is often difficult because of variance and
heterogenity of the reference populations, and perhaps this is
one reason why the role of these markers in pancreatic
cancer is not yet clearly established. The patient population
of this prospective study consists of a consecutive series of
patients with jaundice and/or cholestasis (n = 133), or with
suspicion of chronic pancreatitis or pancreatic tumour
(n = 60), and therefore it can be regarded as a relevant
reference population in the diagnosis of pancreatic cancer.
In the ROC analysis of the current study all marker tests
reached considerably high sensitivities (77-81%) at the
specificity level of 80%. The CA 242 test was significantly
more sensitive than CEA and CA 50 at high specificity levels
(>0.90), but slightly less sensitive at low specificity levels
(<0.60). The CEA test and CA 50 test performed equally
well at high and low specificity levels (Figure 1). This analysis
shows that the CA 242 test has a clear advantage over CEA
and CA 50 because of its higher specificity, confirming thus
the results of previous studies (Haglund et al., 1989; Kuusela
et al., 1991; Nilsson et al., 1992; Pasanen et al., 1992).
The cut-off values recommended by the manufacturers for
CEA (2.5 ng ml-') for CA 50 (17 Uml-'), and for CA 242
(20 U ml-') are based on healthy blood donors. When we
used these levels for our patients, very high (92-96%) sen-
sitivities were reached for CEA and CA 50, but the
specificities remained low (<60%). The sensitivity of CA
242 was inferior (61.5%) to that of CEA or CA 50, but its
specificity was clearly higher (79%). The ROC analysis of
this study suggests that higher cut-off values for CEA and
CA 50 should be used in order to optimise their use in the
diagnosis of pancreatic cancer. Especially the specificity of
these tests seems unacceptably low in the patients with jaun-
dice and/or cholestasis. It has been shown in many studies
that elevated CEA and CA 50 levels are seen in hepatocel-
lular diseases and in benign biliary obstructions (Begent et
al., 1984; Kalser et al., 1978; Lurie et al.,1975; Carr-Locke et
al., 1980; Haglund et al., 1987). According to this study, it
would seem optimal to use a cut-off level for CEA almost
two times higher (4.1 ngml-') than what has been recom-
mended, and an almost ten times higher level for CA 50
(137U ml-'), since they gave a sensitivity of 77% at the
specificity levels of 83% and 84%, respectively. For CA 242
the optimal cut-off level would be 21 U ml-', giving the
sensitivity and specificity of 81%.
In conclusion, the ROC curve analysis of this study shows
that the CA 242 test has an advantage over CEA and CA 50
because of its higher specificity in the diagnosis of pancreatic
cancer. In addition, it would seem reasonable to use clearly
higher cut-off values than what has been recommended for
CEA and CA 50 in the diagnosis of pancreatic cancer, but
for CA 242 the recommended value of 20 U ml-' seems
appropriate. We propose that the ROC curve analysis should
always be performed when a new tumour marker test is
introduced or when different tests are compared, and special
emphasis should be put on the relevance of the study popula-
tion.
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